Plasma syndecan-1 in hemodialysis patients associates with survival and lower markers of volume status by Koch, Josephine et al.
  
 University of Groningen
Plasma syndecan-1 in hemodialysis patients associates with survival and lower markers of
volume status
Koch, Josephine; Idzerda, Nienke M. A.; Dam, Wendy; Assa, Solmaz; Franssen, Casper F.
M.; van den Born, Jacob
Published in:
American journal of physiology-Renal physiology
DOI:
10.1152/ajprenal.00252.2018
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Final author's version (accepted by publisher, after peer review)
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Koch, J., Idzerda, N. M. A., Dam, W., Assa, S., Franssen, C. F. M., & van den Born, J. (2019). Plasma
syndecan-1 in hemodialysis patients associates with survival and lower markers of volume status.
American journal of physiology-Renal physiology, 316(1), F121-F127.
https://doi.org/10.1152/ajprenal.00252.2018
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 21-05-2020
 Running head: Syndecan-1 during hemodialysis.   
Page 1 of 21 
Plasma Syndecan-1 in Hemodialysis Patients Associates with Survival and Lower 1 
Markers of Volume Status 2 
Josephine Koch1, Nienke M. A. Idzerda1, Wendy Dam1, Solmaz Assa1,2, Casper F.M. 3 
Franssen1 and Jacob van den Born1 4 
1Department of Nephrology and 2Department of Cardiology, University Medical Center 5 
Groningen, University of Groningen, Groningen, the Netherlands 6 
Please address correspondence to: 7 
 Jacob van den Born 8 
 Department of Internal Medicine, Division of Nephrology 9 
 De Brug, 4th floor, AA53 10 
 University Medical Center Groningen 11 
 Hanzeplein 1 12 
 9713 GZ Groningen 13 
 The Netherlands 14 
 Tel NR: +31 50 361 0475; Fax NR: +31 50 361 9310  15 






Downloaded from www.physiology.org/journal/ajprenal by ${individualUser.givenNames} ${individualUser.surname} (129.125.166.142) on November 7, 2018.
Copyright © 2018 American Physiological Society. All rights reserved.
 Running head: Syndecan-1 during hemodialysis.   
Page 2 of 21 
 22 
Author contributions  23 
J. Koch, S. Assa, C.F.M. Franssen and J. van den Born conceived and designed the study; 24 
S. Assa and C.F.M. Franssen executed the clinical part of the study; J. Koch, N.M.A. Idzerda 25 
and W. Dam performed the laboratory measurements; J. Koch, N.M.A. Idzerda, C.F.M. 26 
Franssen and J. van den Born analyzed and interpreted the data and drafted the manuscript. 27 
All authors approved the final version of the manuscript.    28 
Downloaded from www.physiology.org/journal/ajprenal by ${individualUser.givenNames} ${individualUser.surname} (129.125.166.142) on November 7, 2018.
Copyright © 2018 American Physiological Society. All rights reserved.
 Running head: Syndecan-1 during hemodialysis.   
Page 3 of 21 
Abstract 29 
Syndecan-1, a transmembrane heparan sulfate proteoglycan, associates with renal and 30 
cardiovascular functioning. We earlier reported syndecan-1 to be involved in renal tubular 31 
regeneration. We now examined plasma values of syndecan-1 in a hemodialysis cohort and 32 
its association with volume, inflammatory and endothelial markers in addition to outcome.  33 
Eighty-four prevalent hemodialysis patients were evaluated for their plasma syndecan-1 34 
levels by ELISA before the start of HD, as well as 60, 180 and 240 minutes after starting 35 
dialysis. Patients were divided into sex-stratified tertiles based on predialysis plasma 36 
syndecan-1 levels. We studied the association between plasma levels of syndecan-1 and 37 
volume, inflammation and endothelial markers and its association with cardiovascular events 38 
and all-cause mortality using Kaplan-Meier curves and cox regression analyses with 39 
adjustments for gender, age, diabetes and dialysis vintage. 40 
Predialysis syndecan-1 levels were two-fold higher in males compared to females 41 
(P=0.0003). Patients in the highest predialysis plasma syndecan-1 tertile had a significantly 42 
higher ultrafiltration rate (P=0.034) and lower plasma values of BNP (P=0.019), pro-ANP 43 
(P=0.024) and endothelin (P<0.0001) compared with the two lower predialysis syndecan-1 44 
tertiles. No significant associations with inflammatory markers were found. Cox regression 45 
analysis showed that patients in the highest syndecan-1 tertile had significantly less CV 46 
events and better survival compared with the lowest syndecan-1 tertile (P=0.02 and P=0.005, 47 
respectively).  48 
In hemodialysis patients, higher plasma syndecan-1 levels were associated with lower 49 
concentrations of BNP, pro-ANP and endothelin, and with better patient survival. This may 50 
suggest that control of volume status in hemodialysis patients allows an adaptive tissue 51 
regenerative response as reflected by higher plasma syndecan-1 levels.  52 
 53 
Key words: hemodialysis; ultrafiltration; inflammation; syndecan-1. 54 
55 
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Introduction 56 
Hemodialysis (HD) patients have a strongly increased cardiovascular (CV) mortality rate 57 
compared to age- and sex-matched healthy individuals. Various factors contribute to this 58 
increased CV mortality, among others uremia, inflammation (1), endothelial dysfunction, 59 
hypertension (2), and volume overload (3), all contributing to accelerated atherosclerosis (4).  60 
Moreover, HD is an inflammatory trigger and induces oxidative stress (5,6) and endothelial 61 
dysfunction (6,7). We hypothesized that in HD patients an adaptive tissue repair response is 62 
induced secondary to tissue injury caused by the aforementioned factors related to renal 63 
failure including volume overload and by HD-induced inflammation, oxidative stress, and 64 
endothelial dysfunction.  Syndecan-1 is suggested as a tissue repair response marker. Upon 65 
injury, syndecan-1 is upregulated and involved in tissue repair responses in different organs 66 
such as the skin (8) or the kidneys (9,10). As a result of cellular shedding, an increase of 67 
plasma syndecan-1 levels can be acutely induced by a number of different stimuli such as 68 
major surgery, inflammatory insults, ischemia-reperfusion, shock, and also during HD 69 
(11,12),  leading to a lower responsiveness status of the cells of origin. In vitro, syndecan-1 70 
shedding can be induced by pro-inflammatory cytokines (13) and a number of growth factors 71 
(14). Syndecan-1 is one of the four transmembrane heparan sulfate proteoglycans (HSPGs) 72 
of the syndecan family. All family members contain a transmembrane core protein to which 73 
glycosaminoglycan side chains are extracellularly attached (15). Syndecan-1 is expressed in 74 
many cell types during development but is down-regulated in most cells after birth (16). In 75 
adults, syndecan-1 is mainly expressed by hepatocytes (17), epithelial cells (18) and plasma 76 
cells (19). Elevated plasma syndecan-1 is usually interpreted as endothelial glycocalyx loss, 77 
and/or shedding from the (renal) epithelium and/or the liver (9,20,21). Shedding is executed 78 
by matrix metalloproteinases (MMPs) and by disintegrin and metalloproteinases (ADAMs), 79 
such as MMP9 and ADAM17 (22). Previous research showed syndecan-1 to be anti-80 
apoptotic, anti-inflammatory and anti-fibrotic (9,10). 81 
In contrast to acutely-induced syndecan-1 shedding, in chronic disease, tissue 82 
syndecan-1 expression reflects an adaptive healing response to the underlying insult, such 83 
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as renal transplantation (10), heart failure (23), and HD treatment (20). As such, plasma 84 
syndecan-1 levels are believed to reflect tissue expression levels of syndecan-1 as the result 85 
of normal turnover (24). However, after initial increase, when damage progressively 86 
increases, tissue syndecan-1 expression diminishes again and cell death and fibrosis take 87 
over. Various renal models showed reduced repair and more inflammation and fibrosis in 88 
syndecan-1 knock-out (KO) mice compared to wild type (WT) animals (10). This is due to its 89 
crucial co-receptor function for regenerative growth factors such as vascular endothelial 90 
growth factor (VEGF) (25), insulin-like growth factor (IGF) (26), and its association with 91 
various integrins (27). By that, syndecan-1 is orchestrating proliferation (25), migration (28) 92 
and adhesion (29). Thus, depending on the stage and severity of the tissue damage, a 93 
positive association (initial disease) or a negative association (progressed disease) is found 94 
between injury and plasma (or tissue) syndecan-1 (9). 95 
Since adaptive tissue repair responses are relevant in the context of HD, the primary study 96 
question was whether pre- and intradialytic plasma syndecan-1 levels in stable HD patients 97 
associate with volume, inflammatory and endothelial markers and with outcome.  98 
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 99 
Patients and Methods: 100 
Patients and Study Design 101 
This study is a post-hoc analysis of the study by Assa et al. (30). In short, HD patients from 102 
the Dialysis Center Groningen and University Medical Center Groningen were eligible for this 103 
study if they were treated with HD for more than 3 months and were on a thrice-weekly HD 104 
schedule. The patients had end-stage chronic kidney disease due to hypertension (n=17), 105 
diabetes (n=12), adult dominant polycystic kidney disease (n=8 ), focal segmental 106 
glomerulosclerosis (n=7), IgA nephropathy (n=4), chronic pyelonephritis (n=2), 107 
glomerulonephritis (n=10), chronic obstructive nephropathy (n=4), other diagnoses (n=8) and 108 
unknown etiology (n=12). The median dialysis vintage was 2.1 years (interquartile range: 0.8 109 
to 4.4 years). Patients with severe heart failure (NYHA stage IV) and patients that did not 110 
have an adequate window for echocardiography imaging were excluded. The original cohort 111 
consisted of 109 patients on conventional HD. Twenty-five subjects were excluded for the 112 
present study due to lack of sufficient plasma for syndecan-1 measurements. All patients 113 
gave written informed consent for participation in this study. The study was performed 114 
according to the principles of the Declaration of Helsinki and was approved by the local 115 
Medical Ethical Committee. The study took place from March 2009 until March 2010. The 116 
follow-up for survival and CV events was 4 years. 117 
 118 
Study Protocol 119 
Patients were studied at the first dialysis session of the week. Dialysis duration was 4 hours. 120 
The assessment of patients’ characteristics took place at study entry. The definition of 121 
diabetes was a fasting blood glucose level of >7 mmol/L or the use of antidiabetic drugs. 122 
Hypertension was defined as predialysis systolic blood pressure above 140 mm Hg and/or 123 
diastolic blood pressure of higher than 90 mm Hg and/or the use of antihypertensive drugs. 124 
We defined cardiovascular history as a history of ischemic heart disease, congestive heart 125 
failure, coronary artery bypass grafting, percutaneous coronary intervention, stroke, or 126 
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peripheral vascular disease. These data were obtained from patients’ medical records. Heart 127 
rate and blood pressure were measured before and after HD. UF rate was expressed as 128 
milliliters per hour per kilogram body weight by dividing UF volume by dialysis session length 129 
and postdialysis target weight (31). Nutritional status was assessed with the 7-point 130 
subjective global assessment (SGA). Patients were defined as malnourished if SGA was 5.  131 
 132 
Laboratory Procedures 133 
Arterial blood was taken from the arterial line before the start of HD, and during HD which 134 
was at 60, 180 and 240 minutes after the start of HD. Hematocrit, leukocytes, neutrophils, 135 
and albumin were measured immediately by routine diagnostics. To determine cytokine 136 
levels, the blood was centrifuged 30 minutes at 3.500 rpm for 15 minutes, after which the 137 
plasma fraction was taken and stored at –80°C. Samples were thawed and recentrifuged 138 
before measurements. Syndecan-1 concentrations were measured in EDTA plasma samples 139 
using sCD138 sandwich ELISA kits (Diaclone, Besancon, France) according to the 140 
manufacturer’s instructions. High-sensitivity C-reactive protein (hs-CRP) was measured by 141 
CRP monoassay (Siemens Healthcare Diagnostics, Newark, DE, USA). Quantikine sandwich 142 
enzyme immunoassay technique (R&D Systems Inc., Minneapolis, MN, USA) was used for 143 
measuring Pentraxin 3 (PTX3), interleukin 6 (IL-6), interleukin-10 (IL-10), soluble intercellular 144 
adhesion molecule 1 (ICAM-1). TNF- was measured by Quantikine HS Human 145 
immunoassay (R&D system, Minneapolis, MN, USA). Von Willebrand factor was measured 146 
by enzyme-linked immunosorbent assay (Dakopatts, Glostrup, Denmark). Endothelin 147 
measurement took place by competing with surface-bound recombinant endothelin 148 
(RayBiotech Inc., Norcross, GA, USA) for binding to a specific antibody (RayBiotech Inc.). By 149 
using substrate conversion of a horseradish peroxidase-labeled secondary antibody we 150 
measured the amount of captured antibody. Proendothelin measurement was done by novel 151 
sandwich fluoroimmunoassay (BRAHMS, Hennigsdorf/ Berlin, Germany) using the 152 
automated system B-R-A-H-M-S KRYPTOR. Plasma angiopoietin-1 (Ang1) and Ang2 levels 153 
were measured via enzyme-linked immunosorbent assay (ELISA) Duosets (R&D systems, 154 
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Minneapolis, USA). The concentration of all biomarkers that were measured during and after 155 
dialysis was corrected for the effect of hemoconcentration according to Schneditz et al. (32). 156 
All stored samples were analyzed at the same time to reduce interassay variability. 157 
Laboratory staff was not aware of patient data or outcome. 158 
 159 
Statistical Analyses 160 
Analyses were performed with IBM SPSS software version 24.0 (IBM, Armonk, NY, USA), 161 
GraphPad Prism version 7.00; GraphPad Software (La Jolla, CA, USA) and R version 3.3.1 162 
(The R Foundation for Statistical computing). Continuous variables with normal distributions 163 
are reported as mean ± standard deviation (SD), skewed variables as median and 164 
interquartile range and categorical data as number and percentage. Normality was tested 165 
with the Shapiro-Wilk test. A (non-parametric) Levene’s test was used to verify the equality of 166 
variances in the data. Correlations between nonparametric variables were calculated using 167 
the Spearman rank correlation coefficient. Comparisons were made with a Wilcoxon Signed 168 
Rank Test, Mann-Whitney U test, Kruskal-Wallis test or one-way analysis of variance 169 
(ANOVA) when appropriate. A Kaplan Meier analysis was used to explore the occurrence of 170 
CV events and mortality across tertiles of baseline syndecan-1 levels. The hazard ratios for 171 
cardiovascular events and mortality across these tertiles were estimated by a Cox 172 
proportional hazard regression model, with adjustment for gender, age, diabetes and dialysis 173 
vintage. Here, log-transformation of syndecan-1 was performed to ensure a linear 174 
relationship between the endpoint and predictor variables. Two-sided P<0.05 was considered 175 
statistically significant. 176 
177 
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The characteristics of the 84 patients in this study are shown in Table 1. One third of the 181 
participants were female. The mean (±SD) age of all patients was 63±16 years. Predialysis 182 
syndecan-1 levels showed a skewed distribution (Figure 1a) and were not associated with 183 
the underlying disease or the use of medications (data not shown). However syndecan-1 184 
levels were found to be two-fold higher in male compared to female patients (P=0.0003) 185 
(Figure 1b). Therefore, patients were categorized into sex-stratified tertiles according to their 186 
plasma syndecan-1 levels, with tertile 1 having low, tertile 2 having intermediate and tertile 3 187 
having high syndecan-1 values (Table 1).  188 
 189 
Associations with predialysis syndecan-1 190 
Age, BMI, body weight, SGA and blood pressure did not differ significantly between 191 
syndecan-1 tertiles (Table 1). Patients in tertile 3 had significantly lower values of BNP 192 
(P=0.019) and pro-ANP (P=0.024) compared with tertile 1 and 2. Levels of endothelin were 193 
significantly lower (P<0.0001) in tertile 3 compared with tertile 1 and 2. Spearman rank 194 
correlation analysis revealed an inverse correlation of predialysis plasma syndecan-1 with 195 
endothelin (R=-0.261; P=0.016) and BNP (R=-0.222; P=0.042). The inflammatory markers 196 
CRP, IL-6 and TNF-α were non-significantly lower in tertile 3 compared with tertile 1 and 2 197 
(Table 1).  198 
 199 
Predialysis syndecan-1 and its association with survival and cardiovascular events 200 
Kaplan-Meier analysis of the predialysis syndecan-1 tertiles demonstrated significantly better 201 
survival (P=0.003) of the patients in tertile 3 compared with tertile 1 (Figure 2a). Patients in 202 
tertile 3 also had fewer CV events compared with tertile 1 (P=0.01) (Figure 2b). Notably, the 203 
survival curves began to separate relatively early during follow-up. Cox regression analysis 204 
showed that also after adjustment for age, sex, diabetes and dialysis vintage patients in 205 
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tertile 3 (hazard ratio for mortality 0.3) had a significantly better survival compared with those 206 
in tertile 1 (hazard ratio for mortality 2.1) (P=0.005). For the same adjustments, cox 207 
regression also showed significantly lower CV events in tertile 3 (hazard ratio for CV events 208 
0.3) compared to tertile 1 (hazard ratio for CV events 1.3) (P=0.02). 209 
 210 
Associations of syndecan-1 with volume and inflammatory markers during hemodialysis  211 
Figure 3a depicts the intradialytic course of plasma syndecan-1 levels. In tertile 3, syndecan-212 
1 levels rose by 18%, although not significant (p=0.7786). In contrast, levels rose significantly 213 
by 6% and 14% in tertile 1 (p<0.0001) and tertile 2 (p=0.0147), respectively. Values 214 
remained significantly different from each other at 240 minutes after start of dialysis. During 215 
HD, hematocrit, endothelin, pro-ANP, and CRP values increased whereas BNP and IL-6 216 
levels decreased (not significant). Patients in tertile 3 had higher hematocrit (not significant) 217 
(Figure 3b) throughout HD as compared with patients in tertile 1. In contrast, patients in 218 
tertile 3 had lower values of endothelin (not significant) (Figure 3d), BNP (P=0.00079) (Figure 219 
3e), pro-ANP (P=0.0269) (Figure 3f), IL-6 (not significant) (Figure 3g), and CRP (not 220 
significant) (Figure 3h) in comparison with the patients in tertile 1 and/or 2. UF rate (Figure 221 
3g) was significantly higher in tertile 3 compared to tertile 1 (P=0.034) (Figure 3c).  222 
223 
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 224 
Discussion 225 
The major findings of this study are that higher plasma syndecan-1 levels associate with 226 
lower plasma levels of BNP, pro-ANP and endothelin, and with higher ultrafiltration rates 227 
during HD. Patients in the highest plasma syndecan-1 tertile also had a significantly lower all-228 
cause mortality and a lower incidence of CV events.  229 
From previous research it is known that dialysis patients have a high incidence of CV 230 
events and related mortality (33). This has been linked to uremia, chronic inflammation (1), 231 
oxidative stress (5), volume overload (3) and endothelial dysfunction (7). The repair response 232 
of tissue damage depends on intrinsic regenerative capacity and stem cells (34), the latter 233 
being reduced in patients with renal failure including HD patients (35). Increased markers of 234 
tissue repair have been reported in several renal studies such as VEGF (9), heparin-binding 235 
EGF (36), and syndecan-1 (9). Just like endothelial markers such as CD31 (37), increased 236 
plasma levels of syndecan-1 have been documented earlier in HD studies where it has been 237 
interpreted as an indicator for endothelial glycocalyx damage (20). 238 
According to our previous observations (9), the syndecan-1 response is bi-phasic 239 
upon increasing injury. With initial injury, a tissue repair process is triggered where 240 
syndecan-1 plays a role which is reflected by higher tissue as well as plasma syndecan-1 241 
values. However, upon progression and chronic development of the underlying damage, 242 
cellular syndecan-1 expression is lost again resulting in an inverse association of syndecan-1 243 
and disease parameters (9). In many situations, where tissue injury is less severe, a positive 244 
association of tissue degradation with syndecan-1 has been reported (10,20). Our research 245 
showed that the patients with the highest plasma syndecan-1 values (tertile 3) had better 246 
survival and fewer CV events. We therefore consider them to have a better clinical and tissue 247 
condition. We could not confirm this by the SGA and inflammatory markers which, however, 248 
showed a trend that support our findings. The CRP and IL-6 tended to be lower in tertile 3 249 
compared with tertile 1, both before and during HD. Furthermore, we found that the patients 250 
in tertile 3 had lower endothelin values suggesting less endothelial dysfunction (38). Also, 251 
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BNP and pro-ANP values were lower in this patient group. These markers are released from 252 
the ventricles and right atrium following wall stress due to hypervolemia (39). Moreover, 253 
patients in tertile 3 also had a higher ultrafiltration rate. These data suggest that the reduced 254 
volume status in the highest syndecan-1 tertile is the consequence of better volume control 255 
during dialysis. Thus, our findings might suggest that lower extracellular volume in dialysis 256 
patients favors the adaptive tissue regenerative response as reflected by higher plasma 257 
syndecan-1 levels. This theory would be in accordance with the findings of Gunal and 258 
colleagues (40). Collectively, these data show that the patients with high plasma syndecan-1 259 
values represent patients with lower extracellular volume and less inflammation and 260 
endothelial dysfunction resulting in improved patient survival.   261 
 At this point, the origin of plasma syndecan-1 in HD patients and the mechanism of its 262 
increased expression and shedding can only be speculated but is often interpreted as 263 
endothelial glycocalyx loss, and/or shedding from the (renal) epithelium and/or the liver 264 
(9,20,21). Previous publications indicate that syndecan-1 transcription is regulated by the 265 
proinflammatory transcription factor NF-B and fibroblast growth factor-inducible response 266 
element that is located on the upper syndecan-1 promoter. Besides, the induction of 267 
syndecan-1 mRNA expression by transforming growth factor as well as EGF has been 268 
shown in vitro. (41) These data indicate syndecan-1 induction under conditions of 269 
inflammation and repair, which is relevant in the context of HD. Adepu et al. (9) reported 270 
enhanced ADAM17 expression in a renal transplantation model in the rat which is a major 271 
syndecan-1 sheddase, but other MMPs could play a role as well (22). A possible trigger of 272 
syndecan-1 shedding is not yet clear. However, systemic inflammation induced by allograft 273 
transplantation showed shedding by proteases such as ADAM17 and an increase of plasma 274 
syndecan-1 (13,42). In our cohort we demonstrated an increase of inflammation and 275 
syndecan-1 during HD.  In vitro studies have shown that inflammatory cytokines, particularly 276 
IL-1, IL-6, and TNF-α, as well as reactive oxygen species are involved in the degradation of 277 
hyaluronan, a major constituent of the glycocalyx (43).  278 
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Nevertheless, syndecan-1 has been shown to be expressed by hepatocytes (17), epithelial 279 
cells (18) and plasma cells (19), but not yet on endothelial cells in vivo (9). Moreover, we 280 
could not find significant associations of plasma syndecan-1 with the endothelial markers 281 
ICAM-1, von Willebrand factor, Ang1 and 2. We therefore suggest that plasma sydecan-1 282 
arises from non-endothelial origin, most likely the liver, epithelial tissues and plasma cells 283 
(9,21). 284 
 In this study, we found a significant difference in plasma levels of syndecan-1 285 
between men and women. This could be explained by different dietary habits (44) and/or 286 
differences in sex-hormones (45) as has been reported before in chronic kidney disease 287 
patients.  288 
 There are some important limitations to the present study. First, the number of 289 
patients was relatively small. Second, no healthy controls were included to extend the 290 
reproduction of earlier studies. Another limitation is that we measured plasma syndecan-1 291 
only once (at baseline). Future studies should investigate whether plasma syndecan-1 levels 292 
change over time and if such changes are related to the patients' clinical situation. 293 
 294 
We conclude that in hemodialysis patients, higher plasma syndecan-1 levels were 295 
associated with lower concentrations of markers of volume status and endothelin, and with 296 
better patient survival. This may suggest that control of volume status in hemodialysis 297 
patients allows an adaptive tissue regenerative response as reflected by higher plasma 298 
syndecan-1 levels. This argues for strict extracellular volume control in HD patients. More 299 
research needs to be done to explore the origin and the (patho-) physiologic roles of 300 
syndecan-1 in HD patients. Lastly, we cannot exclude the possibility that the loss of tissue 301 
syndecan-1 expression, resulting in low plasma values, induces a pro-inflammatory condition 302 
associated with increased extracellular volume. 303 
304 
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 441 
Figure 1: Distribution of predialysis plasma syndecan-1 in stable hemodialysis 442 
patients. (a) Number of patients (frequency) and the skewed distribution of their predialysis 443 
plasma syndecan-1 levels (ng/ml). (b) Distribution of predialysis plasma syndecan-1 levels 444 
(ng/ml) for all patients and for men and women, respectively (median and interquartile range) 445 
showing men to have significantly higher plasma syndecan-1 levels compared to women. 446 
Mann-Whitney U test ***P=0.0003. 447 
448 
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 449 
Figure 2: Predialysis plasma syndecan-1 is associated with survival and lower 450 
cardiovascular events. (a) Kaplan-Meier survival curve showing the association between 451 
predialysis plasma syndecan-1 (indicated in tertiles) and overall survival. **Log-rank test 452 
P=0.003 (b) Kaplan-Meier curve depicting the association between predialysis plasma 453 
syndecan-1 and CV events. *Log-rank test P=0.01. 454 
455 
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 456 
Figure 3: Volume, endothelial and inflammatory parameters shown in plasma 457 
syndecan-1 tertiles during hemodialysis session. Mann-Whitney U test for comparing 458 
different groups. Wilcoxon signed rank test for comparing within the same group. (a) 459 
Syndecan-1 increases over time with tertile 1 (****P<0.0001) and 2 (*P=0.0147) being 460 
statistically significant. At 240 minutes, all tertiles are statistically different from each other, 461 
with tertile 3 showing the highest values. Tertiles 1 and 2 **P=0.0017. Tertiles 1 and 3 462 
****P<0.0001. Tertiles 2 and 3 ***P=0.0003. Hematocrit (b) increase over time where tertile 3 463 
remains to have the highest values. Endothelin (d), pro-ANP (f), and CRP (h) increase over 464 
time with tertile 3 having the lowest values. Only pro-ANP is statistically significant (tertile 1 465 
and 3 *P=0.0269). BNP (e) and IL-6 (g) decrease over time. Tertile 3 has lower values than 466 
tertile 2 with BNP being significant (**P=0.0079). UFR (c) shows the highest values in tertile 467 
3. Tertile 1 and 3 being statistically significant (*P=0.034). 468 
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Table 1. Patient characteristics according to sex-stratified tertiles of plasma syndecan-1. 1 
 All Tertile 1 Tertile 2 Tertile 3 p-value 
N 84 27 28 29  
Predialysis plasma syndecan-1 (ng/mL) 48 (26 – 90) 21 (14 – 33) 51 (32 – 59) 133 (88 – 256) <0.0001 
Men (%) 65 67 64 66  
Plasma syndecan-1 in men (ng/mL) 57 (37 – 129) 28 (16 – 37) 56 (51 – 69) 157 (123 – 256) <0.0001 
Women (%) 35 33 36 34  
Plasma syndecan-1 in women (ng/mL) 30 (20 – 41) 17 (11 – 20) 29 (25 – 33) 50 (39 – 256) <0.0001 
Patient characteristics 
Age (years) 63 ± 16 66 ± 16 61 ± 14 61 ± 16 0.442 
BMI (kg/m²) 25 (23 – 28) 24 (23 – 28) 26 (24 – 28) 24 (23 – 30) 0.462 
SGA  6 (6 – 7) 6 (6 – 6) 6 (6 – 7) 6 (5 – 7) 0.922 
Dialysis vintage (years)  2.1 (0.8 – 4.4) 3.9 (1 – 4.5) 2.1 (0.8 – 4.0) 2.2 (0.7 – 4.0) 0.463 
Residual diuresis (ml/day) 0 (0 – 590) 0 (0 – 300) 0 (0 – 650) 0 (0 – 585) 0.792 
Weight after HD (kg) 77 (68 – 88) 72 (64 – 81) 75 (67 – 89) 78 (73 – 88) 0.432 
Intradialytic weight loss (kg) 1.95 (1.30 – 2.60) 1.80 (1.35 – 2.30) 2.05 (1.35 – 2.78) 2.00 (1.30 – 2.70) 0.468 
Intradialytic weight loss/body weight  0.026 (0.018–0.034) 0.025 (0.018–0.030) 0.027 (0.019-0.037) 0.026 (0.016–0.034) 0.626 
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Predialysis systolic pressure (mmHg) 138 (124 – 155) 137 (124 – 163) 145 (125– 165) 141 (123 – 154) 0.600 
Predialysis Diastolic pressure (mmHg) 79 (69 – 89) 78 (70 – 89) 80 (68 – 98) 78 (72 – 88) 0.831 
Heart Rate (bpm) 73 ± 14 74 ± 14 73 ± 18 71 ± 13 0.500 
Inflammatory markers 
CRP (mg/dl) 6.7 (2.5 – 11.8) 6.7 (2.1 – 18.4) 5 (2.6 – 8.8) 4.3 (1.2 – 8.5) 0.247 
IL-6 (pg/ml) 5.8 (3.9 – 8.6) 7.7 (4.0 – 14.2) 5.4 (3.0 – 8.5) 5.4 (3.4 – 7.2) 0.113 
IL-10 (pg/ml) 0.4 (0.3 – 0.6) 0.4 (0.3 – 0.8) 0.4 (0.3 – 0.5) 0.4 (0.3 – 0.6) 0.749 
PTX3 (ng/ml) 2.57 (1.6 – 4.0) 2.6 (1.6 – 4.5) 2.5 (1.6 – 4.3) 2.4 (1.6 – 3.1) 0.729 
TNF-α (pg/ml) 3.8 ± 1.9 4.4 ± 3.1 3.6 ± 1.2 3.5 ± 0.9 0.155 
Endothelial markers      
Endothelin (pg/ml) 39 (24 – 66) 44 (29 – 72) 43 (25 – 68) 28 (15 – 47) <0.0001 
Pro-endothelin (pg/ml) 280 ± 69 285 ± 71 272 ± 55 284 ± 74 0.012 
ICAM-1 (ng/ml) 141 (125 – 158) 140 (125 – 147) 149 (128 – 174) 138 (113 – 158) 0.320 
Von Willebrand factor (%) 117 (93 – 148) 126 (102 – 146) 118 (90 – 150) 111 (93 – 151) 0.727 
Angiopoetin-1 (ng/mL) 3113 (1956 – 5299) 3480 (2467 – 5460) 2870 (1868 – 5357) 3126 (1787 – 4473) 0.501 
Angiopoetin-2 (ng/mL) 2668 (1558 – 4477) 2899 (2045 – 4914) 2825 (1482 – 4643) 2394 (1580 – 3648) 0.435 
Hematology and Blood 
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Sodium (mEq/L) 138 (136 – 140) 138 (135 – 140) 139 (136 – 140) 137 (136 – 141) 0.847 
Albumin (g/dl) 39 (37 – 41) 40 (38 – 42) 38 (37 – 40) 40 (38 – 42) 0.05 
Lymphocytes (x109/l) 1.3 (1.0 – 1.6) 1.4 (1.0 – 1.6) 1.4 (1.0 – 1.8) 1.3 (1.0 – 1.4) 0.533 
Leukocytes (x109/l) 7.3 ± 2.5 7.9 ± 1.9 7.4 ± 2.5 6.6 ± 1.9 0.463 
Neutrophils (x109/l) 4.6 (3.6 – 6.0) 5.4 (3.9 – 6.6) 4.0 (3.0 – 5.0) 4.8 (4.0 – 6.0) 0.079 
Hematocrit (decimal fraction) 0.35 (0.32 – 0.37) 0.35 (0.33 – 0.37) 0.36 (0.32 – 0.38) 0.35 (0.32 – 0.37) 0.732 
Blood volume markers 
BNP (pg/ml)  351 (176 – 759) 560 (208 – 923) 375 (227 - 740) 213 (119 – 390) 0.019 
NT-proBNP (pg/ml) 3997 (1706 – 8605) 5774 (1970 – 10390) 4763 (2981 – 9867) 2494 (1176 – 5925) 0.066 
Pro-ANP (pmol/l) 794 (557 – 1133) 834 (602 – 1249) 858 (645 – 1133) 597 (464 – 828) 0.024 
 2 
Normally distributed data are shown as means SD, skewed distributed data are shown as medians with interquartile ranges in parentheses, and 3 
categorical distributed variables are shown as numbers and percentages [n (%)]. Abbreviations: BMI: body mass index; BNP, brain natriuretic 4 
peptide; CRP: C-reactive protein; HD: hemodialysis; ICAM-1: Intercellular Adhesion Molecule 1; IL: interleukin; NT-proBNP: N-terminal pro b-5 
type natriuretic peptide; N: number; pro-ANP: pro-atrial natriuretic peptide; PTX3: pentraxin-3; SGA: Subjective Global Assessment; TNF-α: 6 
tumor necrosis factor α.  7 
 8 
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